文献速递MDS 与骨髓增殖性肿瘤

GIPSS:基于遗传学特征的原发性骨髓纤维化预后评分系统

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
PubMed 文献 · Leukemia · 2018-03-23

该研究基于641例原发性骨髓纤维化(PMF)患者的遗传学标记,建立了仅依赖遗传风险因素的GIPSS四层预后模型,各风险组中位生存期分别为26.4、8.0、4.2和2年,内部验证显示其预测准确性可与MIPSS70-plus媲美。

要点

  • GIPSS仅基于遗传标记(核型、CALR、ASXL1、SRSF2、U2AF1)预测PMF生存。
  • 四层风险组中位生存期:低危26.4年,中危-1 8.0年,中危-2 4.2年,高危2年。
  • GIPSS预测准确性经内部验证与MIPSS70-plus相当。

核心结论

  • GIPSS为PMF提供了一种仅依赖遗传风险因素的低复杂度预后工具,其本质具有前瞻性。

研究设计与样本

  • 研究纳入641例有细胞遗传学注释且对既往已知不良突变有信息的PMF患者,采用多变量分析建立预后模型。

主要发现

  • 多变量分析确定极高高危(VHR)核型、不良核型、CALR 1型/类突变缺失以及ASXL1、SRSF2或U2AF1Q157突变存在为生存不良的独立预测因素,对应HR(95%CI)分别为3.1(2.1-4.3)、2.1(1.6-2.7)、2.1(1.6-2.9)、1.8(1.5-2.3)、2.4(1.9-3.2)和2.4(1.7-3.3)。
  • 基于HR加权风险评分构建四层GIPSS模型:低危(0分;n=58)、中危-1(1分;n=260)、中危-2(2分;n=192)和高危(≥3分;n=131)。
  • 各风险组中位(5年)生存期分别为26.4(94%)、8.0(73%)、4.2(40%)和2(14%)年。
  • 模型经自举法内部验证,其预测准确性显示与MIPSS70-plus相当。

关键数值与推荐

  • GIPSS风险评分:低危0分,中危-1 1分,中危-2 2分,高危≥3分。
  • 风险因素HR:VHR核型3.1(2.1-4.3),不良核型2.1(1.6-2.7),CALR 1型/类突变缺失2.1(1.6-2.9),ASXL1突变1.8(1.5-2.3),SRSF2突变2.4(1.9-3.2),U2AF1Q157突变2.4(1.7-3.3)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

International collaborations over the years have produced a series of prognostic models for primary myelofibrosis (PMF), including the recently unveiled mutation-enhanced international prognostic scoring systems for transplant-age patients (MIPSS70 and MIPSS70-plus). In the current study, we considered the feasibility of a genetically inspired prognostic scoring system (GIPSS) that is exclusively based on genetic markers. Among 641 cytogenetically annotated patients with PMF and informative for previously recognized adverse mutations, multivariable analysis identified "VHR" karyotype, "unfavorable" karyotype, absence of type 1/like CALR mutation and presence of ASXL1, SRSF2, or U2AF1Q157 mutation, as inter-independent predictors of inferior survival; the respective HRs (95% CI) were 3.1 (2.1-4.3), 2.1 (1.6-2.7), 2.1 (1.6-2.9), 1.8 (1.5-2.3), 2.4 (1.9-3.2), and 2.4 (1.7-3.3). Based on HR-weighted risk points, a four-tiered GIPSS model was devised: low (zero points; n = 58), intermediate-1 (1 point; n = 260), intermediate-2 (2 points; n = 192), and high (≥3 points; n = 131); the respective median (5-year) survivals were 26.4 (94%), 8.0 (73%), 4.2 (40%), and 2 (14%) years; the model was internally validated by bootstrapping and its predictive accuracy was shown to be comparable to that of MIPSS70-plus. GIPPS offers a low-complexity prognostic tool for PMF that is solely dependent on genetic risk factors and, thus, forward-looking in its essence.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018. PMID: 29654267. doi:10.1038/s41375-018-0107-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。